Cargando…

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiako Meyo, Manuela, Jouinot, Anne, Giroux-Leprieur, Etienne, Fabre, Elizabeth, Wislez, Marie, Alifano, Marco, Leroy, Karen, Boudou-Rouquette, Pascaline, Tlemsani, Camille, Khoudour, Nihel, Arrondeau, Jennifer, Thomas-Schoemann, Audrey, Blons, Hélène, Mansuet-Lupo, Audrey, Damotte, Diane, Vidal, Michel, Goldwasser, François, Alexandre, Jérôme, Blanchet, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072584/ https://www.ncbi.nlm.nih.gov/pubmed/32085544 http://dx.doi.org/10.3390/cancers12020473

Ejemplares similares

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy
por: Peranzoni, Elisa, et al.
Publicado: (2017)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage
por: Icard, Philippe, et al.
Publicado: (2020)

Updated Prognostic Factors in Localized NSCLC
por: Garinet, Simon, et al.
Publicado: (2022)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
por: Peranzoni, Elisa, et al.
Publicado: (2018)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
por: Mansuet-Lupo, Audrey, et al.
Publicado: (2014)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
por: Tlemsani, Camille, et al.
Publicado: (2023)

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
por: Jouinot, Anne, et al.
Publicado: (2018)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma
por: Saade, Anastasia, et al.
Publicado: (2018)

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
por: Pécuchet, Nicolas, et al.
Publicado: (2015)

Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration
por: Bougherara, Houcine, et al.
Publicado: (2015)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells
por: Bennett Saidu, Nathaniel Edward, et al.
Publicado: (2018)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa
por: Millet, Aurélien, et al.
Publicado: (2021)

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas
por: Tlemsani, Camille, et al.
Publicado: (2019)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Influence of stromal elements on resident T cell migration in human and murine tumors analyzed by real-time imaging
por: Peranzoni, Elisa, et al.
Publicado: (2015)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib
por: Younes, Mohamad, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pudbfdt5kts1gvfa0n8jj3kp85